Page 109 - Read Online

Page 14 of 16 Cadamuro et al. Hepatoma Res 2022;8:11 https://dx.doi.org/10.20517/2394-5079.2021.140

56. Melum E, Karlsen TH, Schrumpf E, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D
polymorphisms. Hepatology 2008;47:90-6. DOI PubMed
57. Tsukagoshi M, Wada S, Yokobori T, et al. Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in
cholangiocarcinoma. Cancer Sci 2016;107:116-22. DOI PubMed PMC
58. Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis 2012;33:949-55. DOI PubMed
59. Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and
therapy. Front Oncol 2019;9:1146. DOI PubMed PMC
60. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor
microenvironment. J Immunol Res 2014;2014:149185. DOI PubMed PMC
61. Zhou SL, Dai Z, Zhou ZJ, et al. CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by
recruiting infiltrative intratumoral neutrophils. Carcinogenesis 2014;35:597-605. DOI PubMed
62. Gu FM, Gao Q, Shi GM, et al. Intratumoral IL-17+ cells and neutrophils show strong prognostic significance in intrahepatic
cholangiocarcinoma. Ann Surg Oncol 2012;19:2506-14. DOI PubMed
63. Kitano Y, Okabe H, Yamashita YI, et al. Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic
cholangiocarcinoma. Br J Cancer 2018;118:171-80. DOI PubMed PMC
64. Zhou Z, Wang P, Sun R, et al. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic
cholangiocarcinoma progression by activating STAT3. J Immunother Cancer 2021;9:e001946. DOI PubMed PMC
65. Takagi S, Miyagawa S, Ichikawa E, et al. Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma.
Hum Pathol 2004;35:881-6. DOI PubMed
66. Hu ZQ, Zhou ZJ, Luo CB, et al. Peritumoral plasmacytoid dendritic cells predict a poor prognosis for intrahepatic
cholangiocarcinoma after curative resection. Cancer Cell Int 2020;20:582. DOI PubMed PMC
67. Panya A, Thepmalee C, Sawasdee N, et al. Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-
differentiated monocyte-derived dendritic cells. Cancer Immunol Immunother 2018;67:1579-88. DOI PubMed
68. Thepmalee C, Panya A, Junking M, Chieochansin T, Yenchitsomanus PT. Inhibition of IL-10 and TGF-β receptors on dendritic cells
enhances activation of effector T-cells to kill cholangiocarcinoma cells. Hum Vaccin Immunother 2018;14:1423-31. DOI PubMed
PMC
69. Diggs LP, Ruf B, Ma C, et al. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic
cholangiocarcinoma. J Hepatol 2021;74:1145-54. DOI PubMed
70. Ma C, Zhang Q, Greten TF. MDSCs in liver cancer: a critical tumor-promoting player and a potential therapeutic target. Cell
Immunol 2021;361:104295. DOI PubMed PMC
71. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol 2018;19:108-19. DOI PubMed
PMC
72. Xu X, Hu J, Wang M, et al. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer. Hepatobiliary Pancreat
Dis Int 2016;15:099-105. DOI PubMed
73. Ruffolo LI, Jackson KM, Kuhlers PC, et al. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated
macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut 2021. DOI PubMed PMC
74. Zhang Q, Ma C, Duan Y, et al. Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma. Cancer
Discov 2021;11:1248-67. DOI PubMed PMC
75. Loeuillard E, Yang J, Buckarma E, et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells
augments PD-1 blockade in cholangiocarcinoma. J Clin Invest 2020;130:5380-96. DOI PubMed PMC
76. Goeppert B, Frauenschuh L, Zucknick M, et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J
Cancer 2013;109:2665-74. DOI PubMed PMC
77. Kasper HU, Drebber U, Stippel DL, Dienes HP, Gillessen A. Liver tumor infiltrating lymphocytes: comparison of hepatocellular and
cholangiolar carcinoma. World J Gastroenterol 2009;15:5053-7. DOI PubMed PMC
78. Vigano L, Soldani C, Franceschini B, et al. Tumor-infiltrating lymphocytes and macrophages in intrahepatic cholangiocellular
carcinoma. Impact on prognosis after complete surgery. J Gastrointest Surg 2019;23:2216-24. DOI PubMed
79. Yugawa K, Itoh S, Yoshizumi T, et al. Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with
tumor-infiltrating lymphocytes. Mod Pathol 2021;34:798-807. DOI PubMed
80. Huang YH, Zhang CZ, Huang QS, et al. Clinicopathologic features, tumor immune microenvironment and genomic landscape of
Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. J Hepatol 2021;74:838-49. DOI PubMed
+
81. Miyazaki K, Morine Y, Imura S, et al. Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8 tumor-
infiltrating lymphocytes as a predictor of prognosis after resection of intrahepatic cholangiocarcinoma. Surg Today 2021;51:1985-95.
DOI PubMed
82. Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res 2018;37:110. DOI PubMed PMC
83. He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res 2020;30:660-9. DOI PubMed PMC
84. Gok Yavuz B, Hasanov E, Lee SS, et al. Current landscape and future directions of biomarkers for immunotherapy in hepatocellular
carcinoma. J Hepatocell Carcinoma 2021;8:1195-207. DOI PubMed PMC
85. Shek D, Akhuba L, Carlino MS, et al. Immune-checkpoint inhibitors for metastatic colorectal cancer: a systematic review of clinical
outcomes. Cancers (Basel) 2021;13:4345. DOI PubMed PMC
86. Xiong W, Zhao Y, Du H, Guo X. Current status of immune checkpoint inhibitor immunotherapy for lung cancer. Front Oncol
2021;11:704336. DOI PubMed PMC